These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 28334759)

  • 1. Highly efficient biallelic genome editing of human ES/iPS cells using a CRISPR/Cas9 or TALEN system.
    Takayama K; Igai K; Hagihara Y; Hashimoto R; Hanawa M; Sakuma T; Tachibana M; Sakurai F; Yamamoto T; Mizuguchi H
    Nucleic Acids Res; 2017 May; 45(9):5198-5207. PubMed ID: 28334759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TALEN- and CRISPR-enhanced DNA homologous recombination for gene editing in zebrafish.
    Zhang Y; Huang H; Zhang B; Lin S
    Methods Cell Biol; 2016; 135():107-20. PubMed ID: 27443922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene Editing With TALEN and CRISPR/Cas in Rice.
    Bi H; Yang B
    Prog Mol Biol Transl Sci; 2017; 149():81-98. PubMed ID: 28712502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Single-Molecule View of Genome Editing Proteins: Biophysical Mechanisms for TALEs and CRISPR/Cas9.
    Cuculis L; Schroeder CM
    Annu Rev Chem Biomol Eng; 2017 Jun; 8():577-597. PubMed ID: 28489428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genome editing: the road of CRISPR/Cas9 from bench to clinic.
    Eid A; Mahfouz MM
    Exp Mol Med; 2016 Oct; 48(10):e265. PubMed ID: 27741224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient Genome Editing in Induced Pluripotent Stem Cells with Engineered Nucleases In Vitro.
    Termglinchan V; Seeger T; Chen C; Wu JC; Karakikes I
    Methods Mol Biol; 2017; 1521():55-68. PubMed ID: 27910041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Applications of Alternative Nucleases in the Age of CRISPR/Cas9.
    Guha TK; Edgell DR
    Int J Mol Sci; 2017 Nov; 18(12):. PubMed ID: 29186020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [CRISPR/Cas9 technology in disease research and therapy: a review].
    Shi M; Shen Z; Zhang N; Wang L; Yu C; Yang Z
    Sheng Wu Gong Cheng Xue Bao; 2021 Apr; 37(4):1205-1228. PubMed ID: 33973436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Site-Specific Genome Engineering in Human Pluripotent Stem Cells.
    Merkert S; Martin U
    Int J Mol Sci; 2016 Jun; 17(7):. PubMed ID: 27347935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genome editing: a robust technology for human stem cells.
    Chandrasekaran AP; Song M; Ramakrishna S
    Cell Mol Life Sci; 2017 Sep; 74(18):3335-3346. PubMed ID: 28405721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Applications of ZFN, TALEN and CRISPR/Cas9 techniques in disease modeling and gene therapy].
    Zhao G; Pu J; Tang B
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2016 Dec; 33(6):857-862. PubMed ID: 27984622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Site-Specific Integration of Exogenous Genes Using Genome Editing Technologies in Zebrafish.
    Kawahara A; Hisano Y; Ota S; Taimatsu K
    Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27187373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A highly efficient method for enriching TALEN or CRISPR/Cas9-edited mutant cells.
    Yasuda H; Kim E; Reza AM; Kim JH
    J Genet Genomics; 2016 Dec; 43(12):705-708. PubMed ID: 27916442
    [No Abstract]   [Full Text] [Related]  

  • 14. TALEN/CRISPR-mediated eGFP knock-in add-on at the OCT4 locus does not impact differentiation of human embryonic stem cells towards endoderm.
    Krentz NA; Nian C; Lynn FC
    PLoS One; 2014; 9(12):e114275. PubMed ID: 25474420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR Base Editing in Induced Pluripotent Stem Cells.
    Chang YJ; Xu CL; Cui X; Bassuk AG; Mahajan VB; Tsai YT; Tsang SH
    Methods Mol Biol; 2019; 2045():337-346. PubMed ID: 31250381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genome Editing During Development Using the CRISPR-Cas Technology.
    Arzate-Mejía RG; Licona-Limón P; Recillas-Targa F
    Methods Mol Biol; 2018; 1752():177-190. PubMed ID: 29564772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene Editing With CRISPR/Cas9 RNA-Directed Nuclease.
    Doetschman T; Georgieva T
    Circ Res; 2017 Mar; 120(5):876-894. PubMed ID: 28254804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Production of genome-edited pluripotent stem cells and mice by CRISPR/Cas.
    Horii T; Hatada I
    Endocr J; 2016; 63(3):213-9. PubMed ID: 26743444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genome Editing in Human Pluripotent Stem Cells.
    Carlson-Stevermer J; Saha K
    Methods Mol Biol; 2017; 1590():165-174. PubMed ID: 28353269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oligonucleotide-Mediated Genome Editing Provides Precision and Function to Engineered Nucleases and Antibiotics in Plants.
    Sauer NJ; Narváez-Vásquez J; Mozoruk J; Miller RB; Warburg ZJ; Woodward MJ; Mihiret YA; Lincoln TA; Segami RE; Sanders SL; Walker KA; Beetham PR; Schöpke CR; Gocal GF
    Plant Physiol; 2016 Apr; 170(4):1917-28. PubMed ID: 26864017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.